Nara Organics Whole Milk Powdered Infant Formula - recalled due to Clostridium botulinum

United States

Nara Organics voluntarily recalling all lots of Nara Organics Powdered Infant Formula currently on the market due to the potential risk of Clostridium botulinum contamination. Three infants were hospitalized in California, Washington, and Pennsylvania. There are no reported deaths. Nara Organics Powdered Infant Formula was distributed nationally across Target retail stores, Target.com, and Nara.com between July 2025 and June 2026. Nara Infant Formula is not distributed outside of the USA.

Affected Product Details:
- Nara Organics Whole Milk Infant Formula, 700g, with UPC 860013251901
- Nara Organics Whole Milk Infant Formula, 400g, with UPC: 860013251918

All lots currently on the market are included in this voluntary recall, and the specific codes are as follows. The lot code can be found on the bottom of each can.

408125075E14F2; 708125076E14F2; 708125083E14F2; 408125139E14F2; 708125141E14F2; 708125145E14F2; 708125174E14F2; 709125273E14F2; 709125280E14F2; 709125288E14F2; 409125307E14F2; 70926019ENNB; 70926029ENNB; 70926035ENNB; 70926039ENNB; 70926042ENNB

The three specific product lots these infants were exposed to are: 709125280E14F2, 709125288E14F2, 708125174E14F2.

The Food and Drug Administration (FDA) and Center for Disease Control (CDC) contacted Nara Organics late Friday, June 12, 2026, and provided information about 3 cases of infant botulism in infants who CDC reported had consumed Nara formula. The three specific product lots these infants were exposed to are: 709125280E14F2, 709125288E14F2, 708125174E14F2. To date, Nara infant formula has not tested positive for C. botulinum. However, Nara is recalling all products currently on the market.

According to the FDA, Infant botulism is a rare but potentially fatal illness that presents a serious threat to the health of infants, which occurs when Clostridium botulinum spores are ingested and colonize the intestinal tract, producing botulinum neurotoxins in the immature gut of infants. Affected infants can present with some or all of the following signs and symptoms: constipation, poor feeding, ptosis (drooping eyelid), sluggish pupils, low muscle tone, difficulty sucking and swallowing, weak or altered cry, generalized weakness, respiratory difficulty, and possibly respiratory arrest.

Source: www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/nara-organics-recalls-all-lots-nara-infant-formula-because-possible-health-risk